Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB<sub>1</sub>) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was developed by Merck & Co.
In October 2008, Merck stopped its phase III clinical trials with the drug due to high level of central nervous system side effects, mainly depression and anxiety.